MétaCan
Menu
← Back to cohort
Record W4397024337 · doi:10.1681/asn.20223311s1545b

Malignancy Risk in Kidney Transplant Recipients Exposed to Immunosuppression Pre-Transplant for the Treatment of Glomerulonephritis

2022· article· en· W4397024337 on OpenAlexaff
David Massicotte‐Azarniouch, Randal K. Detwiler, Yichun Hu, Ronald J. Falk, Manish K. Saha, Susan L. Hogan, Vimal K. Derebail

Bibliographic record

VenueJournal of the American Society of Nephrology · 2022
Typearticle
Languageen
FieldMedicine
TopicRenal Transplantation Outcomes and Treatments
Canadian institutionsUniversity of Ottawa
Fundersnot available
KeywordsImmunosuppressionMalignancyMedicineRenal transplantKidney transplantGlomerulonephritisKidney transplantationInternal medicineKidney

Abstract

fetched live from OpenAlex

Background: Kidney transplant patients with glomerulonephritis (GN) as their native disease may be exposed to significant amounts of pre-transplant immunosuppression (PTI), which could increase the risk for the development of malignancy post-transplant. Methods: We conducted a single-center, retrospective study of adult and pediatric kidney transplant recipients at University of North Carolina Hospitals from January 2005 until May 2020. Patients with GN as their native kidney disease who received PTI for the treatment of GN (n=184) were compared to a control cohort (n=579) of non-diabetic, non-PTI receiving kidney transplant patients. We calculated hazard ratios (HR) with 95% confidence intervals (95%CI) for the outcomes of the first occurrence of solid or hematologic malignancy, non-melanoma skin cancer (NMSC) and post-transplant lymphoproliferative disorder (PTLD). Results: Over a median follow-up of 5.7 years, PTI for GN was associated with significantly increased risk for malignancy compared to controls (13.0% vs 9.7% respectively, adjusted HR 1.82 [95%CI 1.10-3.00]), but not for NMSC (10.3% vs 11.4% respectively, adjusted HR 1.09 [95%CI 0.64-1.83]) nor PTLD (3.3% vs 3.1% respectively, adjusted HR 1.02 [95%CI 0.40-2.61]). The risk for malignancy was significantly increased in those who received cyclophosphamide (HR 2.59 [95%CI 1.48-4.55]) or rituximab (HR 3.82 [95%CI 1.69-8.65]) pre-transplant, and particularly in those who received both cyclophosphamide and rituximab, but not for calcineurin inhibitors nor mycophenolate. Conclusions: The use of PTI for treatment of GN, in particular cyclophosphamide or rituximab, is associated with increased risk for development of solid or hematologic malignancy post-transplant.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.293
Teacher spread0.276 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of Nephrology→Same topicRenal Transplantation Outcomes and Treatments→French-language works237,207→